Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | MPO | P05164 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118916 | 1.00 | TAAR1 (0.60) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL7650103 | 0.94 | TAAR1 (0.58) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL31277350 | 0.94 | TAAR1 (0.58) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL29474956 | 0.88 | TAAR1 (0.64) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL852646 | 0.88 | TAAR1 (0.64) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL7831226 | 0.87 | TAAR1 (0.69) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL2201042 | 0.84 | TAAR1 (0.60) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| Ethylene Glycol SCHEMBL28055624 | 0.84 | ALOX5 (0.64) | TAAR1MPOALOX5PTGS2 | |
| SCHEMBL17024100 | 0.83 | HRH1 (0.46) | TAAR1MPO | |
| SCHEMBL6172042 | 0.83 | ALOX5 (0.50) | TAAR1MPOALOX5PTGS2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118222171-A | Nanometer stamping adhesive for improving adhesive force of glass-based circuit and circuit manufacturing method based on glass substrate | 深圳市百柔新材料技术有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-113035408-B | Solar cell grid line slurry and preparation method thereof, and solar cell | 深圳市百柔新材料技术有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-113035408-A | Solar cell grid line paste and preparation method thereof, and solar cell | 深圳市百柔新材料技术有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-106317898-A | Photocured organosilicone elastomer and preparation method and application thereof | 广东工业大学 | 2017-01-11 | — | — | CN | claimed |
| EP-2072083-B1 | Utilisation of 2.4'-dimethyl-propiophenon as an aroma | SYMRISE AG (DE) | 2012-02-15 | — | — | EP | claimed |
| US-20090162308-A1 | USE OF 2,4'-DIMETHYLPROPIOPHENONE AS A FRAGRANCE SUBSTANCE | SYMRISE GMBH & CO. KG (DE) | 2009-06-25 | — | — | US | claimed |
| EP-2072083-A1 | Utilisation of 2.4'-dimethyl-propiophenon as an aroma | Symrise GmbH & Co. KG (DE) | 2009-06-24 | — | — | EP | claimed |
| CN-118398276-A | Silver-coated copper slurry, and strong light curing process and application thereof | 华中科技大学温州先进制造技术研究院 | 2024-07-26 | — | — | CN | disclosed |
| CN-118222171-A | Nanometer stamping adhesive for improving adhesive force of glass-based circuit and circuit manufacturing method based on glass substrate | 深圳市百柔新材料技术有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-113035408-B | Solar cell grid line slurry and preparation method thereof, and solar cell | 深圳市百柔新材料技术有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117069720-A | 5-HT 2A Receptor agonist, preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667256-A | Compounds for treating diseases and methods of treating diseases | 艾特里提治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-5145865-A | Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1992-09-08 | — | — | US | disclosed |
| EP-0393607-A2 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0004835-B1 | ETHANOLAMINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR MEDICINAL USE | Aktiebolaget DRACO (SE) | 1981-10-14 | — | — | EP | disclosed |
| US-4177339-A | CARBONATE COMPOUNDS AND ADDITION POLYMERS THEREOF | PHILIP MORRIS INCORPORATED (US) | 1979-12-04 | — | — | US | disclosed |
| EP-0004835-A1 | Ethanolamine compounds, processes for their preparation, pharmaceutical preparations containing them and their medicinal use | Aktiebolaget DRACO (SE) | 1979-10-17 | — | — | EP | disclosed |
| US-4092988-A | POLYCARBONATES | PHILIP MORRIS INCORPORATED (US) | 1978-06-06 | — | — | US | disclosed |
| US-3959190-A | ALKYL SULFIDE- CROSSLINKED POLYSTYRENE | DYNAPOL (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162308-A1 | USE OF 2,4'-DIMETHYLPROPIOPHENONE AS A FRAGRANCE SUBSTANCE | CYP1B1, CYP4A22, ROS1 | TAAR1 2219/4885MPO 1426/4885SIGMAR1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.